Goodwin Guides Arlington Capital Partners on $1.45 Billion Sale of Riverpoint Medical to Novanta
The Private Equity team guided Arlington Capital Partners (“Arlington”) on entering a definitive agreement to sell Riverpoint Medical, a category leader in high-growth minimally invasive surgical consumables, to Novanta Inc. (“Novanta”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs). Under the terms of the agreement, Novanta will acquire all outstanding equity interests of the parent company, Riverpoint Medical, for an upfront cash consideration of $1.2 billion and a milestone payment of $250 million in the first quarter of 2027. The transaction is expected to close in the third quarter of 2026, subject to customary regulatory approvals and closing conditions.
Arlington Capital Partners is a Washington, DC-area private investment firm specializing in government-regulated industries. Focused on the healthcare, aerospace and defense, and government services and technology sectors, the firm partners with founders and entrepreneurs to build platforms of strategic importance to national priorities. Operating in markets with high barriers to entry, Arlington looks to partner with organizations within these industries that save lives, improve effectiveness, and reduce costs. Since inception in 1999, Arlington has invested in over 200 companies and raised over $14 billion in committed capital. The firm is currently investing out of its $6 billion Fund VII.
The Goodwin team was led by Josh Klatzkin, Matt Mauney, Mike Amalfe, and Amina Mokel.
For more information on the deal, please read the press release.